Table 1.
Summary of cancers with Dynamin 2 mutations or overexpression
| Type of cancer | DNM2 defect | Phenotypic association | References |
|---|---|---|---|
| Acute Lymphoblastic leukemia (adult and children) | Somatic Mutations |
• High risk of treatment failure • Poor prognosis (adult) |
[29, 30] |
| Acute Lymphoblastic leukemia | Overexpression |
• Cell proliferation • Poor prognosis |
[31] |
| Chronic myeloid leukemia | Overexpression | [32] | |
| Ovarian | Overexpression | [33] | |
| Bladder | Overexpression | • Correlated with grade progression | [34] |
| Papillary Thyroid cancer | Overexpression | • Poor prognosis | [35] |
| Prostate | Overexpression |
• Aggressiveness • Mortality |
[36, 37] |
| Cervical | Overexpression | • Biomarker in grading neoplasia | [38, 39] |
| Breast | Overexpression |
• Relapse to chemotherapy in triple negative breast cancer • Cytoplasmic DNM2 in invasive ductal carcinoma • Plasma membrane DNM2 ➔ aggressiveness • Nuclear DNM2 staining correlated with tumor stages |
[40, 41] |
| Pancreas | Overexpression |
• Cell migration and invasion • Lower man survival times |
[42] |